Misonidazole neuropathy. A prospective study
Research output: Contribution to journal › Journal article › Research › peer-review
The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.
Original language | English |
---|---|
Journal | Journal of Neuro-Oncology |
Volume | 6 |
Issue number | 3 |
Pages (from-to) | 227-30 |
Number of pages | 4 |
ISSN | 0167-594X |
DOIs | |
Publication status | Published - Nov 1988 |
- Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Laryngeal Neoplasms/complications, Male, Middle Aged, Misonidazole/adverse effects, Nervous System Diseases/chemically induced, Pharyngeal Neoplasms/complications
Research areas
ID: 275603866